Atelerix Life Sciences

  • info@atelerixlifesciences.com
Facebook Twitter Linkedin

[vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

INTRODUCTION

[/vc_column_text][vc_column_text]

  • Unmet Need:Every year, millions of US surgical patients experience opioid-induced respiratory depression (OIRD) severe enough to require prolonged mechanical ventilation and longer hospital stays
  • Problem:Current drug for OIRD, Naloxone, restores breathing but is problematic, and therefore used infrequently, because it  reverses pain relief
  • Solution:New drug, ATLX-0199 (sometimes referred to as Sudaxine), reverses OIRD while preserving pain relief
  • Market:Over 1$ billion annually
  • Technology:Proprietary small molecule platform; strong animal data; NIH-backed
  • Team:Experienced, industry-known, motivated, committed
  • Stage:Late pre-clinical

[/vc_column_text][vc_empty_space][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

THE PROBLEM

[/vc_column_text][vc_column_text]

While useful in controlling pain opioids have significant limitations:

[/vc_column_text][vc_separator type=”normal”][vc_column_text]

  • Life-threatening respiratory and cardiovascular reactions
  • Withdrawal/tolerance/addiction
  • GI (motility) disruption
  • Potential for mass casualties

[/vc_column_text][vc_empty_space][vc_column_text]

Opioid-induced side effects have created unmet medical needs of crisis proportion, affecting millions of people annually.

[/vc_column_text][vc_empty_space][vc_empty_space][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

THE PROBLEM: OIRD

[/vc_column_text][vc_empty_space][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_column_text]

46% of patients receiving opioids during and following surgery experience opioid-induced respiratory depression (OIRD)*:

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”2/3″][vc_column_text]

  • OIRD is a life-threatening side effect of opioids characterized by respiratory depression or cardiac collapse
  • It affects millions of hospital patients every year
  • OIRD extends hospital stays by 3 days on average
  • Longer hospitalization increases costs by over $6,000
  • Our solution addresses a $1 billion market

[/vc_column_text][vc_column_text]OIRD in hospitalized patients is Atelerix’s first target indication for opioid-related unmet medical needs.[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/3″][vc_column_text]

* Source: Medtronic Prodigy Study, 2020[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_empty_space][vc_column_text]

THE PROBLEM: WEAPONIZATION

[/vc_column_text][vc_empty_space][vc_column_text]

The opioid crisis has a new and even uglier dimension – weaponization – and the focused funding interest of the NIH and the United States military.

[/vc_column_text][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”1/2″][vc_single_image image=”193″ img_size=”full” qode_css_animation=””][/vc_column_inner][vc_column_inner width=”1/2″][vc_column_text]

“These public health threat agents are highly toxic chemicals that could cause mass casualties after either deliberate terrorism-related release or inadvertently.”

– National Institutes of Health[/vc_column_text][vc_separator type=”normal”][vc_column_text]Russian special forces soldiers are seen carrying out hostages killed by a highly potent weaponized opioid in a Moscow theatre after a three-day stand off with Chechen terrorists.

(Credit: Anton Denisov/AFP/Getty Images)[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_empty_space][vc_column_text]

THE PROBLEM: ADDICTION / TOLERENCE / OVERDOSE / WITHDRAWAL

[/vc_column_text][vc_empty_space][vc_column_text]

Overdose deaths from synthetic opioids (primarily fentanyl) have become a massive crisis, approaching 40,000 in 2019, and growing since COVID-19 :

[/vc_column_text][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner][vc_single_image image=”196″ img_size=”full” qode_css_animation=””][vc_column_text]

Atelerix’s novel approach to opioid-induced unmet medical needs could potentially diminish the number of opioid-related deaths

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_empty_space][vc_column_text]

CURRENT STANDARD HAS SIGNIFICANT DISADVANTAGES

[/vc_column_text][vc_empty_space][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”1/4″][vc_single_image image=”258″ img_size=”full” alignment=”center” style=”vc_box_border” border_color=”blue”][/vc_column_inner][vc_column_inner width=”3/4″][vc_column_text]

Naloxone restores breathing but also:

  • Immediately reverses opioid analgesia, leaving surgical patients in pain
  • Short-acting, requiring frequent re-administration
  • Less effective against highly-potent, synthetic opioids
  • Can cause cardio-pulmonary arrest

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]

Much of the on-going research for the treatment of OIRD directly targets opioid receptors, with limited results; Atelerix’s ATLX-0199 technology takes a different approach.

[/vc_column_text][vc_separator type=”normal”][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_empty_space][vc_column_text]

A BETTER SOLUTION

[/vc_column_text][vc_empty_space][vc_column_text]

ATLX-0199, an active thiol-based compound from our platform of novel drugs, reverses opioid-induced side effects such as OIRD while preserving pain relief:

[/vc_column_text][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”1/2″][vc_column_text]

  • ATLX-0199 targets molecular pathways, modulating signals downstream from activated opioid receptors
  • Concept validated by extensive NIH-supported research/data
  • Atelerix is developing ATLX-0199 and other compounds in its pipeline to treat the range of opioid-induced side effects; first focus is OIRD in the hospital surgical setting

[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_single_image image=”259″ img_size=”full” alignment=”center”][/vc_column_inner][/vc_row_inner][vc_separator type=”normal”][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][vc_column_text]

ATLX-0199 TARGET MARKET

Opportunity for OIRD in surgical setting is over $1 billion annually

[/vc_column_text][/vc_column][/vc_row][vc_row row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_empty_space][vc_column_text]

  • 51 million Americans undergo inpatient surgery annually
  • 80% of surgical patients will receive opioids for their surgery
  • 46% of those patients will experience some level of OIRD
  • 4.7% of those patients will experience OIRD of a severity sufficient to qualify as an opioid-related adverse drug event (ORADE) – This represents our initial target market

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”260″ img_size=”full” alignment=”center”][vc_column_text]

“Adjusted for covariates, presence of an ORADE is associated with 32% higher cost of hospitalization, 45% longer post-operative length of stay, 36% lower odds of discharge home, and 2.2 times the odds of death.”*

*The Burden of OIRD-Related Adverse Drug Events on Hospitalized Previously Opioid-Free Surgical Patients, Richard D. Urman, MD; J Patient Safety, March 2021[/vc_column_text][vc_empty_space][vc_separator type=”normal”][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][vc_column_text]

FUNDING TO DATE

Over $16 million in prior non-dilutive funding to Atelerix Scientific Co-founders

[/vc_column_text][vc_empty_space][vc_single_image image=”261″ img_size=”full” alignment=”center”][vc_column_text]Company has exclusive option on resulting intellectual property[/vc_column_text][vc_empty_space][vc_empty_space][/vc_column][/vc_row]